bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
2seventy bio Research Deep Dive Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy Read more about 2seventy bio Research Deep Dive Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy
2seventy bio Research Deep Dive Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy Read more about 2seventy bio Research Deep Dive Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy
2seventy bio Announces Upcoming Investor Events Read more about 2seventy bio Announces Upcoming Investor Events
2seventy bio at Morgan Stanley 19th Annual Healthcare Conference Read more about 2seventy bio at Morgan Stanley 19th Annual Healthcare Conference
bluebird bio Secures $75 Million in Private Placement Equity Financing Read more about bluebird bio Secures $75 Million in Private Placement Equity Financing
bluebird bio at Morgan Stanley 19th Annual Healthcare Conference Read more about bluebird bio at Morgan Stanley 19th Annual Healthcare Conference
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events Read more about bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update Read more about bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
2021 Wedbush PacGrow Healthcare Conference Read more about 2021 Wedbush PacGrow Healthcare Conference